...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: wonder if...
2
Oct 24, 2016 02:17PM

Oct 24, 2016 03:09PM

The primary endpoint of the BETonMACE trial is time to first occurence of strict 3-point major adverse cardiac events (MACE): cardiovascular death, non-fatal myocardial infarction, non-fatal stroke. Those are cardiovascular outcomes. Since the finalization of trial design last year, BETonMACE has always been a cardiovascular outcomes trial (CVOT).

7
Oct 24, 2016 05:59PM
Share
New Message
Please login to post a reply